Premium
Antidementia drug use in Japan: Bridging the research‐to‐practice gap
Author(s) -
Okumura Yasuyuki,
Sakata Nobuo
Publication year - 2018
Publication title -
international journal of geriatric psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.28
H-Index - 129
eISSN - 1099-1166
pISSN - 0885-6230
DOI - 10.1002/gps.4892
Subject(s) - health economics , bridging (networking) , health insurance , metropolitan area , welfare , political science , library science , medicine , health care , law , pathology , computer network , computer science
In 2015, there were 47 million people with dementia worldwide. The overall number of people with dementia is projected to reach 132 million in 2050, 51% of whom will be from Asian countries. Japan has the highest prevalence of dementia among the OECD countries, where 2% of inhabitants (5 million) are living with dementia. There are significant unmet needs regarding the effectiveness of antidementia drug use in real‐world settings. Populations in settings of clinical trials on antidementia drugs generally deviate from those in clinical practice settings (eg, exclusion of people aged ≥85 years).